Retatrutide (LY3437943) is an investigational triple-agonist (GLP-1, GIP, glucagon) and is not an approved therapy
Sourcing quality, dosing precision, contraindications, and individual biology all matter and they require a clinician who understands both the science and your specific situation
It is administered subcutaneously and supports flexible dosing frequencies, including micro-dosing, multiple weekly injections, or a once-weekly flex titration schedule
This intensive phase is designed to quickly restore healthy B12 levels and address symptoms as soon as possible
Beyond that, this format supports extended research protocols, dose-finding studies, and multiple cohort administrations without reordering
Always check the compound's data sheet before choosing a diluent